No Detail Found!

Weight loss in HCV patients can be used as a surrogate marker for evaluation of interferon (IFN-a) treatment efficacy – A prospective pilot study.

Author(s)
Ibrar Alam Institute of Biotechnology and Genetic Engineering (IBGE), KP Agricultural University Peshawar, Pakistan;Department of Biotechnology, Bacha Khan University Charsadda, Charsadda, KPK, Pakistan
Iftikhar Alam Department of Human Nutrition & Dietetics, Bacha Khan University Charsadda, Charsadda, KPK, Pakistan;Tübingen Ageing and Tumour Immunology Group, Zentrum für Medizinische Forschung, University of Tübingen, Waldhörnlestraße 22, D-72072 Tübingen, Germany
Ijaz Ali Institute of Biotechnology and Genetic Engineering (IBGE), KP Agricultural University Peshawar, Pakistan
Muhammad Ali Department of Biotechnology, Bacha Khan University Charsadda, Charsadda, KPK, Pakistan
Abstract
The aim of the study was to investigate whether weight loss followed the same pattern in HCV patients (‘responders’ and ‘non-responders) after interferon (IFN-α) treatment. A total of 20 male HCV positive patients (mean age 33.1±9.9) in Peshawar, Pakistan participated in this study. They were initially tested as HCV positive, and were given IFN/Ribavarin treatment for 6 months. Changes in body weight (BW), lean body mass (LBM) and body fat (BF) were monitored on monthly basis. End to treatment response (ETR) was established by a final undetectable HCV RNA in serum at the end of therapy and the patients were categorized as either ‘responders’ or ‘non-responders’. The results show a total of 12 out of 20 patients as ‘responders’ (60%). All patients lost weight and the mean weight loss in ‘responders’ and ‘non-responders’ was 6.2 (±1.5) and 5.8 (±1.4) Kg, respectively. There was a significant difference in the mean change in BW, LBM, and BF between ‘responders’ and ‘non-responders’ during the last 3 month period only. This suggests that difference in drug response in HCV starts from month 4 and onwards (i.e. during the last 3 months). In conclusion, weight trends during treatment should be monitored as weight loss may be used as a surrogate marker for ERT to the current standard of care.
Publication Details
Page(s) 571-576
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 27, Issue: 3, Year: 2014

Request the full text from PASTIC

0

Citations

0

Downloads

98

Views